Table 2.

Demographics and laboratory data of 139 patients with AAV and renal involvement.

PR3-ANCA n = 67MPO-ANCA n = 72p
Sex, F/M24/4336/360.092
Diagnosis: GPA/MPA/EGPA42/25/09/62/1
Age at diagnosis, yrs64.8 ± 16.470.1 ± 14.30.043
Diagnosis delay, mos2 (1–3)2 (1–4)0.206
Laboratory results
  C-reactive protein, mg/dl11.8 (8.8–17.7)4.6 (0.9–12.6)< 0.001
  ESR, mm/h80.1 ± 29.664.2 ± 36.00.047
  Hemoglobin, g/dl10.8 ± 1.8910.2 ± 1.680.05
  Thrombocyte count, × 109/l387 (314–483)316 (260–386)0.001
  White blood cell count, × 109/l12.5 (10–15)9.3 (7.1–12.5)0.001
  Creatinine at diagnosis, mg/dl2.64 (1.37–4.10)3.05 (1.73–5.77)0.062
  Creatinine at last followup*, mg/dl1.19 (0.85–1.60)1.39 (1.01–1.84)0.187
Patients with GFR < 50 ml/min at last followup*, n (%)12/35 (34)13/27 (48)0.243
Patients developed ESRD, n (%)10 (15)27 (38)0.003
Patients with ≥ 3 organ systems involved, n (%)50 (75)42 (58)0.042
Death, n (%)29 (43)35 (49)0.529
Organ system involved at diagnosis
  General, n (%)64 (96)60 (83)0.021
  ENT, n (%)31 (46)9 (13)< 0.001
  Chest, n (%)32 (48)29 (40)0.374
  Nervous, n (%)7 (10)4 (6)0.286
  Cutaneous, n (%)4 (6)3 (4)0.627
  Mucocutaneous and eyes, n (%)5 (7)1 (1)0.078
  Cardiovascular, n (%)2 (3)3 (4)0.709
  Abdominal, n (%)4 (6)8 (11)0.281
Renal histology findings, n (%)
  Diffuse crescentic GN, pauciimmune15 (22)11 (15)0.282
  Diffuse crescentic GN, IF not done2 (3)3 (4)0.585
  Diffuse crescentic GN, granular IgG/C31 (1.5)2 (3)0.602
  Focal necrotizing/crescentic GN, pauciimmune24 (36)22 (31)0.509
  Focal necrotizing/crescentic GN, IF not done3 (4.5)8 (11)0.147
  Pauciimmune small vessel vasculitis without GN0 (0)3 (4)0.091
  Miscellaneous or insufficient material for diagnosis5 (8)8 (11)0.46
No renal biopsy performed17 (25)15 (21)0.525
  • * Data on creatinine and GFR < 50 ml/min at last followup (May 2012), included only patients alive and with native kidney function at last followup. All other demographic, clinical, and laboratory data are based on 139 patients with renal involvement. Results are reported as mean ± SD (normally distributed variables) or median and interquartile range (not normally distributed variables), or number and percentage. AAV: ANCA-associated vasculitis; GPA: granulomatosis with polyangiitis (formerly Wegener); MPA: microscopic polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); ESRD: endstage renal disease; ENT: ear-nose-throat; GN: glomerulonephritis; ESR: erythrocyte sedimentation rate; ANCA: anti-neutrophil cytoplasmic antibody; PR3: proteinase 3; MPO: myeloperoxidase; GFR: glomerular filtration rate; IF: immunofluorescence.